Products for Research Use Only

Tegaserod

CAT: 0804-HY-14153-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14153-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research[1][2][3].
CAS Number
145158-71-0
UNSPSC
12352005
Hazard Statement
H317, H410
Target
5-HT Receptor; Apoptosis
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/tegaserod.html
Purity
99.89
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
COC1=CC=C(NC=C2/C=N/NC(NCCCCC)=N)C2=C1
Molecular Formula
C16H23N5O
Molecular Weight
301.39
Precautions
H317, H410
References & Citations
[1]Wei Liu, et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020 Feb 21;39 (1) :38.|[2]M D Crowell, et al. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol Motil. 2005 Oct;17 (5) :738-43.|[3]D T Beattie, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143 (5) :549-60.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
5-HT2 Receptor; Apolipoprotein D
Citation 01
Int Immunopharmacol. 2025 Sep 23:162:115181.|Nat Commun. 2025 Feb 7;16 (1) :1087.|Mol Med. 2025 Jan 29;31 (1) :30.

Popular Products